National Institute for Health and Clinical Excellence (NICE)
NICE issues standard on improving maternal and child nutrition
A quality standard to help improve maternal and child nutrition was published yesterday by the National Institute for Health and Care Excellence.
A healthy diet is important for women who may become pregnant, as the woman's nutrition influences how her baby grows and develops and lays the foundations for her child's health. The mother's own health also depends on how well-nourished she is before, during and after pregnancy.
During the early years of a child's life, their diet has an effect on their growth and development. Diet is linked to many common childhood conditions such as iron-deficiency anaemia, tooth decay and vitamin D deficiency. It can also affect the risk of developing conditions such as coronary heart disease, diabetes and obesity in adult life.
The new standard aims to support improved nutrition for women who may become pregnant before, during and after pregnancy (up to a year after birth), and for babies and pre-school children. With a focus on low-income and other disadvantaged households, the standard is expected to contribute to improving outcomes in areas including postnatal depression, childhood illnesses and infections and iron-deficiency anaemia.
Professor Gill Leng, Deputy Chief Executive of NICE, said: “Good nutrition before, during and after pregnancy benefits the growth and development of the baby and the health of the mother. Women who may become pregnant need to be aware of the importance of a healthy diet as there’s most benefit from good nutrition before conception and in the first 12 weeks of pregnancy. There’s a strong link between poor maternal and child nutrition and deprivation, so improving the nutritional status of mothers and pre-school children who are disadvantaged is vital.
"The quality statements set out the priority actions to enable better nutrition for women who become pregnant and their children – such as advice on eating healthily during pregnancy, and support for breastfeeding. Making sure that these priority steps are put into practice will help to improve the health of mothers-to-be and give their babies the best start in life.”
The quality statements include:
- Pregnant women attending antenatal and health visitor appointments are advised how to eat healthily in pregnancy
- Women with a BMI of 30 or more following childbirth are offered a structured weight-loss programme
- Pregnant women and parents and carers of children under 4 years who may be eligible for the Healthy Start scheme are given information and support to apply
- Women receive breastfeeding support from a service that uses an evaluated, structured programme.
NICE has also issued a separate quality standard to help improve the care of people with drug allergies and ensure they are spared from serious harm. The quality standard includes 6 statements with priorities for healthcare professionals on how best to document allergies and how this information should be shared across NHS services as well as with patients themselves.
For more information call the NICE press office on 0300 323 0142, or out of hours on 07775 583 813.
Notes to Editors
About the NICE quality standard
- The standard, ‘Nutrition: Improving maternal and child nutrition’ is available at: http://www.nice.org.uk/guidance/qs98.
- The standard, ‘Drug allergy: diagnosis and management’ is available at: http://www.nice.org.uk/guidance/qs97.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for driving improvement and excellence in the health and social care system. We develop guidance, standards and information on high-quality health and social care. We also advise on ways to promote healthy living and prevent ill health.
Our aim is to help practitioners deliver the best possible care and give people the most effective treatments, which are based on the most up-to-date evidence and provide value for money, in order to reduce inequalities and variation.
Our products and resources are produced for the NHS, local authorities, care providers, charities, and anyone who has a responsibility for commissioning or providing healthcare, public health or social care services.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy07/05/2021 16:15:00
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy.
NICE announces more people eligible for nusinersen following review of Managed Access Agreement04/05/2021 14:15:00
NICE has today (4 May 2021) announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen (also called Spinraza and made by Biogen) following a review of data collected as part of the Managed Access Agreement (MAA).
New draft guidance aims to achieve fairer outcomes for looked-after children and young people30/04/2021 16:15:00
Looked after children and young people should be considered ‘one of their own’ by carers, in order to help them to reach their full potential, new NICE draft guidelines say
NICE signs up to join the GetReal Institute29/04/2021 09:15:00
NICE’s ambition complements the GetReal Institute’s core mission to facilitate the adoption and implementation of real-world evidence in health care decision-making.
Thousands with high cholesterol set to benefit from new treatment on the NHS28/04/2021 14:15:00
Thousands of people with high cholesterol will soon have access to a new treatment option on the NHS as a result of final NICE guidance published today (28 April 2021).
NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation28/04/2021 09:15:00
NICE yesterday (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).
NICE recommends new treatment for rare blood disorder23/04/2021 11:15:00
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
Chemotherapy-free treatment option to be offered to patients with England’s most common leukaemia21/04/2021 13:05:00
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer21/04/2021 11:15:00
NICE yesterday (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.